Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo